Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Cash from Financing Activities for 6 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 99.24% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, down 99.31% year-over-year, with the annual reading at $4.9 million for FY2025, 99.31% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.9 million at Janux Therapeutics, up from $493000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $386.6 million in Q4 2024, with the low at -$843000.0 in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $61.3 million, with a median of $954000.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities crashed 2454.55% in 2021, then skyrocketed 157900.0% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $164000.0 in 2021, then grew by 16.46% to $191000.0 in 2022, then skyrocketed by 335.08% to $831000.0 in 2023, then soared by 46428.28% to $386.6 million in 2024, then plummeted by 99.24% to $2.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.9 million, $493000.0, and $954000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.